90002-56-5

Basic information

• Product Name: N-(2-AMINOETHYL) 4-BROMOBENZENESULFONAMIDE
• Synonyms: N-(2-AMINOETHYL) 4-BROMOBENZENESULFONAMIDE;N-(2-AMINOETHYL)-4-BROMOBENZENESULPHONAMIDE;N-(2-Aminoethyl)-4-bromobenzenesulphonamide 96%;N-(2-Aminoethyl)-4-bromobenzenesulphonamide96%
• CAS NO: 90002-56-5
• Molecular Formula: C₈H₁₁BrN₂O₂S
• Molecular Weight: 279.15
• Product Categories: blocks;Bromides;Sulfonamides
• Mol File: 90002-56-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 112-114
• Boiling Point: 394.9 °C at 760 mmHg
• Flash Point: 192.6 °C
• Appearance: /
• Density: 1.582 g/cm³
• Vapor Pressure: 1.91E-06mmHg at 25°C
• Storage Temp.: 2-8°C
• PKA: 11.18±0.10(Predicted)
• CAS DataBase Reference: N-(2-AMINOETHYL) 4-BROMOBENZENESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-AMINOETHYL) 4-BROMOBENZENESULFONAMIDE(90002-56-5)
• EPA Substance Registry System: N-(2-AMINOETHYL) 4-BROMOBENZENESULFONAMIDE(90002-56-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 90002-56-5(Hazardous Substances Data)

Usage

General Description

"N-(2-aminoethyl) 4-bromobenzenesulfonamide" is a chemical compound with the molecular formula C8H10BrNO2S. It is a derivative of sulfonamide, commonly used as a pharmaceutical intermediate in the synthesis of various medications. N-(2-AMINOETHYL) 4-BROMOBENZENESULFONAMIDE contains a bromo substituent on the benzene ring, making it useful in the development of drugs targeting specific biological pathways. The aminoethyl group also allows for the formation of potential hydrogen bonds with other molecules, enhancing its pharmaceutical properties. "N-(2-aminoethyl) 4-bromobenzenesulfonamide" has the potential to be a key building block in the development of new drugs for various medical conditions.

InChI:InChI=1/C8H11BrN2O2S/c9-7-1-3-8(4-2-7)14(12,13)11-6-5-10/h1-4,11H,5-6,10H2/p+1

Upstream product

• 98-58-8 4-bromobenzenesulfonyl chloride 
• 107-15-3 ethylenediamine 
• 2576-47-8 2-bromoethylamine hydrobromide 

Relevant articles and documents

Anticancer profile and anti-inflammatory effect of new N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives

A new series of N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives 11a-o were designed and synthesized based on our previous works. The new series was tested for its anticancer and anti-inflammatory effects. The anticancer profile of

Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening

BRAF mutation is commonly known in a number of human cancer types. It is counted as a potential component in treating cancer. In this study, based on structural optimization of previously reported inhibitors (3-fluro substituted derivatives of imidazo[2,1-b]thiazole-based scaffold), we designed and synthesized sixteen new imidazo[2,1-b]thiazole derivatives with m-nitrophenyl group at position 6. The electron withdrawing properties was reserved while the polarity was modified compared to previously synthesized compounds (-F). Furthermore, the new substituted group (–NO2) provided an additional H-bond acceptor(s) which may bind with the target enzyme through additional interaction(s). In vitro cytotoxicity evaluation was performed against human cancer cell line (A375). In addition, in vitro enzyme assay was performed against mutated B-Raf (B-Raf V600E). Compounds 13a, 13g and 13f showed highest activity on mutated B-Raf with IC50 0.021, 0.035 and 0.020 μM. All target compounds were tested for in vitro cytotoxicity against NCI 60 cell lines. Compounds 13a and 13g were selected for 5 doses test mode. Moreover, in silico molecular simulation was explored in order to explore the possible interactions between the designed compounds and the B-Raf V600E active site.

Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold

In this work, a new series of imidazo[2,1-b]thiazole was designed and synthesized. The new compounds are having 3-fluorophenyl at position 6 of imidazo[2,1-b]thiazole and pyrimidine ring at position 5. The pyrimidine ring containing either amide or sulphonamide moiety attached to a linker (ethyl or propyl) at position 2 of the pyrimidine ring. The final compounds were selected by NCI for in vitro cytotoxicity screening. Most derivatives showed cytotoxic activity against colon cancer and melanoma cell lines. In addition, IC50s of the target compounds were determined over A375 and SK-MEL-28 cell lines using sorafenib as positive control. Compounds12b, 12c, 12e, 12f, 15a, 15d, 15f, 14g and 15h exhibited superior activity when compared to sorafenib. The most potent compounds were tested against wild type BRAF, v600e BRAF, and CRAF. Compound 15h exhibited a potential inhibitory effect againstV600EBRAF (IC50 = 9.3 nM).